loading
Precedente Chiudi:
$2.2102
Aprire:
$2.25
Volume 24 ore:
1,361
Relative Volume:
0.11
Capitalizzazione di mercato:
$25.59M
Reddito:
-
Utile/perdita netta:
$-3.15M
Rapporto P/E:
-10.78
EPS:
-0.2069
Flusso di cassa netto:
$-2.23M
1 W Prestazione:
+5.19%
1M Prestazione:
+0.45%
6M Prestazione:
+9.31%
1 anno Prestazione:
-39.73%
Intervallo 1D:
Value
$2.19
$2.25
Intervallo di 1 settimana:
Value
$1.8302
$2.52
Portata 52W:
Value
$1.20
$5.50

Cytomed Therapeutics Ltd Stock (GDTC) Company Profile

Name
Nome
Cytomed Therapeutics Ltd
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
34
Name
Cinguettio
Name
Prossima data di guadagno
Name
Ultimi documenti SEC
Name
GDTC's Discussions on Twitter

Confronta GDTC con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
GDTC 2.23 25.59M 0 -3.15M -2.23M -0.2069
VRTX 446.52 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.51 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 592.50 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.90 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.19 24.49B 3.30B -501.07M 1.03B 11.54

Cytomed Therapeutics Ltd Borsa (GDTC) Ultime notizie

pulisher
Nov 20, 2024

CytoMed Therapeutics : Update on Clinical Milestone CytoMed Therapeutics Announces First Patient Dosed in its First in Human Phase I Clinical Trial of Allogeneic CAR Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematologica - Marketscreener.com

Nov 20, 2024
pulisher
Nov 20, 2024

Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance

Nov 20, 2024
pulisher
Oct 23, 2024

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Simply Wall St

Oct 23, 2024
pulisher
Oct 17, 2024

Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch

Oct 17, 2024
pulisher
Oct 16, 2024

Osteopore Partners with CytoMed in Regenerative Medicine - TipRanks

Oct 16, 2024
pulisher
Oct 08, 2024

CytoMed begins clinical trial for innovative cancer therapy - Investing.com

Oct 08, 2024
pulisher
Oct 07, 2024

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank - Marketscreener.com

Oct 07, 2024
pulisher
Oct 07, 2024

Cytomed Therapeutics announces NMRC co-funding support for ANGELICA trial - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

CytoMed Launches Innovative CAR-T Cell Trial - TipRanks

Oct 07, 2024
pulisher
Oct 07, 2024

CytoMed begins clinical trial for innovative cancer therapy By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

CytoMed Therapeutics’ first-in-human Phase I ANGELICA - GlobeNewswire

Oct 07, 2024
pulisher
Oct 07, 2024

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - StockTitan

Oct 07, 2024
pulisher
Oct 04, 2024

CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine - Yahoo Finance

Oct 04, 2024
pulisher
Oct 03, 2024

CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed's strategy to cord blood-derived biologics through subsidiary, LongevityBank - The Manila Times

Oct 03, 2024
pulisher
Oct 03, 2024

CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire

Oct 03, 2024
pulisher
Sep 30, 2024

GDTCCytoMed Therapeutics Limited Ordinary Shares Latest Stock News & Market Updates - StockTitan

Sep 30, 2024
pulisher
Sep 30, 2024

CYTOMED THERAPEUTICS : AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K - Marketscreener.com

Sep 30, 2024
pulisher
Sep 30, 2024

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire

Sep 30, 2024
pulisher
Sep 30, 2024

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates - Yahoo Finance

Sep 30, 2024
pulisher
Sep 25, 2024

Presenting on the Emerging Growth Conference 75 Day 2 on September 26 - GlobeNewswire

Sep 25, 2024
pulisher
Aug 25, 2024

CytoMed Therapeutics Limited acquired the licence and certain assets of Cellsafe International Sdn Bhd from Cellsafe Biotech Group for MYR 2.3 million. - Marketscreener.com

Aug 25, 2024
pulisher
Aug 20, 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now - GlobeNewswire

Aug 20, 2024
pulisher
Jul 25, 2024

CytoMed Therapeutics (NASDAQ:GDTC) Trading Down 2% - Defense World

Jul 25, 2024
pulisher
Jul 17, 2024

CytoMed Therapeutics Ltd (GDTC) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Jul 17, 2024
pulisher
Jul 17, 2024

CytoMed Therapeutics Acquires Cord Blood Banking Licence - GlobeNewswire

Jul 17, 2024
pulisher
Jul 17, 2024

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire

Jul 17, 2024
pulisher
Jul 17, 2024

Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now - GlobeNewswire Inc.

Jul 17, 2024
pulisher
Jun 27, 2024

CytoMed Therapeutics Limited Announces Board and Audit Committee Changes - Marketscreener.com

Jun 27, 2024
pulisher
Jun 20, 2024

CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off ... - Quantisnow

Jun 20, 2024
pulisher
Jun 20, 2024

CytoMed Therapeutics to Ring Nasdaq Closing Bell - Quantisnow

Jun 20, 2024
pulisher
Jun 20, 2024

CytoMed Therapeutics Limited Announces Closing of US$9,649,476 Firm Commitment Initial Public Offering - Quantisnow

Jun 20, 2024
pulisher
Jun 20, 2024

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Quantisnow

Jun 20, 2024
pulisher
Jun 20, 2024

CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo ... - Quantisnow

Jun 20, 2024
pulisher
Jun 20, 2024

A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has ... - Quantisnow

Jun 20, 2024
pulisher
Jun 20, 2024

CytoMed Therapeutics : Board re organization Form 6 K - Marketscreener.com

Jun 20, 2024
pulisher
Jun 12, 2024

Natural Alternatives International (NASDAQ:NAII) Receives New Coverage from Analysts at StockNews.com - Defense World

Jun 12, 2024
pulisher
Jun 12, 2024

Viridian Therapeutics (NASDAQ:VRDN) Receives New Coverage from Analysts at Wolfe Research - Defense World

Jun 12, 2024
pulisher
Jun 11, 2024

Anti-aging Therapeutics Market Size, Scope, Growth and Forecast to 2031 - InsightAce Analytic

Jun 11, 2024
pulisher
May 24, 2024

CytoMed Therapeutics : Annual Shareholders MeetingForm 6-K - Marketscreener.com

May 24, 2024
pulisher
Mar 20, 2024

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - Yahoo Finance

Mar 20, 2024
pulisher
Mar 18, 2024

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies - Marketscreener.com

Mar 18, 2024
pulisher
Mar 04, 2024

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair - GlobeNewswire

Mar 04, 2024
pulisher
Feb 07, 2024

Healthcare Stocks Moving Wednesday: OGEN, FEMY, JSPR, ABEO, GDTC, CING, HUMA, NEXI - InvestorsObserver

Feb 07, 2024
pulisher
Jan 29, 2024

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - Yahoo Finance

Jan 29, 2024
pulisher
Jan 23, 2024

GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView

Jan 23, 2024
pulisher
Dec 05, 2023

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology - PR Newswire

Dec 05, 2023
pulisher
Nov 17, 2023

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PR Newswire

Nov 17, 2023
pulisher
Oct 24, 2023

Cytomed Therapeutics Limited (GDTC-Q) QuotePress Release - The Globe and Mail

Oct 24, 2023
pulisher
Sep 25, 2023

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology - PR Newswire

Sep 25, 2023
pulisher
Aug 16, 2023

CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency - 팜뉴스

Aug 16, 2023
pulisher
Jul 25, 2023

Novel T-Cell Immunotherapies Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic

Jul 25, 2023

Cytomed Therapeutics Ltd Azioni (GDTC) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Capitalizzazione:     |  Volume (24 ore):